GRAND RAPIDS–Corium Pharma Solutions Inc., a contract development and manufacturing organization, today announced its new name, Corium Innovations Inc. Company officials said the name change reflects the company’s ongoing focus on offering cutting-edge drug delivery capabilities and solutions.
Corium Innovations has decades of experience in groundbreaking transdermal technology to deliver innovative development, manufacturing. The company is committed to finding new ways to bring the benefits of its proprietary transdermal, transmucosal and microarray delivery platforms to different patient and consumer groups in customary or challenging usage situations. Additional details can be found at https://www.coriuminv.com.
This name change reflects the company’s ongoing focus on offering cutting-edge drug delivery capabilities and solutions.
“As we are focused on building the most innovative and successful specialty contract development and manufacturing organization in our industry, we took this opportunity to ensure that our outward identity reflects our inward focus – starting with our name and corporate branding,” said Dr. Mark Sirgo, Chief Executive Officer. “I’m confident about the promise of our future and excited to introduce the name and visual identity, which bring that promise to life.”
The company was founded in 1995 in Grand Rapids and acquired by Gurnet Point Capital in 2018. Corium Innovations was formed in October 2022 through an investment by Webster Equity Partners for more than $400 million in value.
More at https://www.coriuminv.com, www.gurnetpointcapital.com, or https://websterequitypartners.com